Logo image of LUCY

INNOVATIVE EYEWEAR INC (LUCY) Stock Fundamental Analysis

NASDAQ:LUCY - Nasdaq - US45791D2080 - Common Stock - Currency: USD

4.55  -0.26 (-5.41%)

After market: 4.45 -0.1 (-2.2%)

Fundamental Rating

4

Taking everything into account, LUCY scores 4 out of 10 in our fundamental rating. LUCY was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While LUCY has a great health rating, there are worries on its profitability. LUCY shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LUCY has reported negative net income.
In the past year LUCY has reported a negative cash flow from operations.
LUCY had negative earnings in each of the past 5 years.
LUCY had a negative operating cash flow in each of the past 5 years.
LUCY Yearly Net Income VS EBIT VS OCF VS FCFLUCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

LUCY has a Return On Assets of -69.28%. This is in the lower half of the industry: LUCY underperforms 75.00% of its industry peers.
Looking at the Return On Equity, with a value of -73.50%, LUCY is doing worse than 60.11% of the companies in the same industry.
Industry RankSector Rank
ROA -69.28%
ROE -73.5%
ROIC N/A
ROA(3y)-207.79%
ROA(5y)N/A
ROE(3y)-601.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LUCY Yearly ROA, ROE, ROICLUCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

LUCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LUCY Yearly Profit, Operating, Gross MarginsLUCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

9

2. Health

2.1 Basic Checks

LUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LUCY has been reduced compared to 1 year ago.
There is no outstanding debt for LUCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LUCY Yearly Shares OutstandingLUCY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M
LUCY Yearly Total Debt VS Total AssetsLUCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M

2.2 Solvency

An Altman-Z score of 6.13 indicates that LUCY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.13, LUCY belongs to the top of the industry, outperforming 83.51% of the companies in the same industry.
LUCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.13
ROIC/WACCN/A
WACC9.05%
LUCY Yearly LT Debt VS Equity VS FCFLUCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 2M -2M 4M -4M -6M

2.3 Liquidity

LUCY has a Current Ratio of 16.83. This indicates that LUCY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LUCY (16.83) is better than 98.40% of its industry peers.
LUCY has a Quick Ratio of 15.43. This indicates that LUCY is financially healthy and has no problem in meeting its short term obligations.
LUCY has a Quick ratio of 15.43. This is amongst the best in the industry. LUCY outperforms 97.87% of its industry peers.
Industry RankSector Rank
Current Ratio 16.83
Quick Ratio 15.43
LUCY Yearly Current Assets VS Current LiabilitesLUCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

7

3. Growth

3.1 Past

LUCY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -219.76%.
Looking at the last year, LUCY shows a very strong growth in Revenue. The Revenue has grown by 159.44%.
The Revenue has been growing by 167.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-219.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.75%
Revenue 1Y (TTM)159.44%
Revenue growth 3Y167.81%
Revenue growth 5YN/A
Sales Q2Q%14.75%

3.2 Future

LUCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.10% yearly.
Based on estimates for the next years, LUCY will show a very strong growth in Revenue. The Revenue will grow by 347.21% on average per year.
EPS Next Y35%
EPS Next 2Y29.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year171.43%
Revenue Next 2Y347.21%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LUCY Yearly Revenue VS EstimatesLUCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 5M 10M
LUCY Yearly EPS VS EstimatesLUCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LUCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUCY Price Earnings VS Forward Price EarningsLUCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUCY Per share dataLUCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5

4.3 Compensation for Growth

LUCY's earnings are expected to grow with 29.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LUCY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNOVATIVE EYEWEAR INC

NASDAQ:LUCY (2/21/2025, 8:00:00 PM)

After market: 4.45 -0.1 (-2.2%)

4.55

-0.26 (-5.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners0.88%
Inst Owner Change-87.84%
Ins Owners40.97%
Ins Owner Change3.39%
Market Cap11.10M
Analysts82.86
Price Target14.28 (213.85%)
Short Float %3.89%
Short Ratio1.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.38%
Min EPS beat(2)-14.58%
Max EPS beat(2)39.34%
EPS beat(4)2
Avg EPS beat(4)1.3%
Min EPS beat(4)-33.05%
Max EPS beat(4)39.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-69.37%
Min Revenue beat(2)-72.37%
Max Revenue beat(2)-66.37%
Revenue beat(4)1
Avg Revenue beat(4)4.21%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)201.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-51.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.11
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-9.66
EYN/A
EPS(NY)-4.08
Fwd EYN/A
FCF(TTM)-2.51
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0.64
BVpS4.48
TBVpS4.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.28%
ROE -73.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-207.79%
ROA(5y)N/A
ROE(3y)-601.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 153.96%
Cap/Sales 12.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.83
Quick Ratio 15.43
Altman-Z 6.13
F-Score5
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)742.78%
Cap/Depr(5y)N/A
Cap/Sales(3y)24.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.75%
EPS Next Y35%
EPS Next 2Y29.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)159.44%
Revenue growth 3Y167.81%
Revenue growth 5YN/A
Sales Q2Q%14.75%
Revenue Next Year171.43%
Revenue Next 2Y347.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-136.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-147.18%
OCF growth 3YN/A
OCF growth 5YN/A